Healthcare | Restructurings

Immucor Completes Debt Restructuring

  • Immucor, Inc. (NASDAQ: BLUD) is a leading supplier of diagnostic reagents and automated instrumentation to ensure the safety of blood transfusions
  • TM Capital was retained by Immucor to assist in restructuring indebtedness following covenant defaults on Immucor’s $42 million credit facility
  • TM Capital assisted Immucor in negotiating a restructuring agreement which waived all defaults, eliminated a potential going concern qualification and minimized financing costs

Client Testimonial